ISRCTN80888941已完成1 期
Bioavailability and tolerability study of two new diclofenac epolamine lecithin gel formulations (2.6% and 3.9%) in comparison with the marketed diclofenac epolamine lecithin gel formulation 1.3% (Effigel® IBSA): an open-label three-way randomised cross-over pilot bioavailability study
IBSA Institut Biochimique S.A0 个研究点目标入组 12 人开始时间: 2017年5月16日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Signed written informed consent
- •2. Males/females, 18-55 year old inclusive
- •3. Body Mass Index (BMI): 18.5-30 kg/m2 inclusive
- •4. Vital signs: systolic blood pressure 100-139 mmHg, diastolic blood pressure 50-89 mmHg, heart rate 50-90 bpm, measured after 5 min at rest in the sitting position
- •5. Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and to comply with the requirements of the entire study.
- •6. Contraception and fertility (women only): women of child-bearing potential were required to use at least one of the following reliable methods of contraception:
- •6.1. Hormonal oral, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit
- •6.2. A non-hormonal intrauterine device or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit
- •6.3. A male sexual partner who agreed to use a male condom with spermicide
- •6.4. A sterile sexual partner
- •Female participants of non-child-bearing potential or in post-menopausal status for at least 1 year were admitted
- •For all female subjects, pregnancy test result had to be negative at screening and day 1
排除标准
- •1. Electrocardiogram (12-leads, supine position): clinically significant abnormalities
- •2. Physical findings: clinically significant abnormal physical findings which could interfere with the objectives of the study
- •3. Laboratory analyses: clinically significant abnormal laboratory values indicative of physical illness
- •4. Allergy: ascertained or presumptive hypersensitivity to the active principle and/or formulations'ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the investigator considered could affect the outcome of the study
- •5. Diseases: significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that could interfere with the aim of the study
- •6. Medications: medications, including over the counter medications and herbal remedies for 2 weeks before the start of the study. Hormonal contraceptives for females were allowed
- •7. Investigative drug studies: participation in the evaluation of any investigational product for 3 months before this study. The 3-month interval was calculated as the time between the first calendar day of the month that followed the last visit of the previous study and the first day of the present study
- •8. Blood donation: blood donations for 3 months before this study
- •9. Drug, alcohol, caffeine, tobacco: history of drug, alcohol [>1 drink/day for females and >2 drinks/day for males, defined according to the USDA Dietary Guidelines 2015-2020)], caffeine (>5 cups coffee/tea/day) or tobacco abuse (=10 cigarettes/day)
- •10. Drug test: positive result at the drug test at screening
- •11. Alcohol test: positive alcohol breath test at day 1
- •12. Diet: abnormal diets (<1600 or >3500 kcal/day) or substantial changes in eating habits in the 4 weeks before this study; vegetarians
- •13. Pregnancy (women only): positive or missing pregnancy test at screening or day 1, pregnant or lactating women
研究者
相似试验
已完成
1 期
Bioavailability and tolerability study of two new DHEP-medicated plasters in comparison with the marketed DHEP medicated plaster 1.3% (Flector®)DHEP-medicated plasterISRCTN96078237IBSA Institut Biochimique S.A12
已完成
1 期
A study of a new primaquine 5 mg formulation in healthy volunteersRBR-105nyj86Fundação Oswaldo Cruz
进行中（未招募）
1 期
A study of three formulations of primaquine in healthy volunteersRBR-27qyp2Fundação Oswaldo Cruz
进行中（未招募）
1 期
Evaluation of efficacy and bioavailability of ibuprofen lysinatePain on an inflammatory basis (otitis and otomastoiditis, adenite, cellulite, arthritis) and post-operative painMedDRA version: 21.0Level: PTClassification code 10050533Term: Pain assessmentSystem Organ Class: 10022891 - InvestigationsMedDRA version: 20.1Level: LLTClassification code 10063374Term: Pain scaleSystem Organ Class: 10022891 - InvestigationsEUCTR2019-000647-27-ITDicofarm S.p.A.84
已完成
1 期
Study aimed to investigate the local tolerability and the availability in blood flow of diclofenac after two applications of a new DHEP-medicated plaster, in comparison with a marketed DHEP-medicated plasterISRCTN25043983IBSA Institut Biochimique (Switzerland)24